CTXR— Citius Pharmaceuticals, Inc.

MaterialsPharmaceuticals$19M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenues	—	—	—	—
Research and development	$9.2M-23.1%	$11.9M-19.7%	$14.8M-16.1%	$17.7M
General and administrative	$18.5M+1.6%	$18.2M+19.3%	$15.3M+30.1%	$11.8M
Stock-based compensation – general and administrative	$10.8M-8.5%	$11.8M+78.9%	$6.6M+69.4%	$3.9M
Total Operating Expenses	$38.5M-8.3%	$42.0M+14.3%	$36.7M+10.3%	$33.3M
Operating Loss	-$38.5M+8.3%	-$42.0M-14.3%	-$36.7M-10.3%	-$33.3M
Interest income	$110K-85.5%	$758K-35.7%	$1.2M+369.1%	$251K
Interest expense	-$268K	—	—	—
Gain on sale of New Jersey net operating losses	$2.4M	—	$3.6M	—
Total Other Income (Expense), Net	-$158K-105.0%	$3.1M-34.0%	$4.8M+1795.4%	$251K
Loss before Income Taxes	-$38.7M+0.4%	-$38.8M-21.5%	-$32.0M+3.3%	-$33.1M
Income tax expense	$1.1M+83.5%	$576K+0.0%	$576K+0.0%	$576K
Net Loss	-$39.7M-0.8%	-$39.4M-21.2%	-$32.5M+3.3%	-$33.6M
Net loss attributable to non-controlling interest	$2.3M+703.6%	$287K	—	—
Deemed dividend on warrant extension	-$1.0M	—	-$1.2M	—
Net Loss Applicable to Common Stockholders	-$37.4M+6.8%	-$40.2M-19.3%	-$33.7M-0.2%	-$33.6M
Net Loss Per Share Applicable to Common Stockholders - Basic (in Dollars per share)	-$3.38+43.4%	-$5.97-7.2%	-$5.57-2321.7%	-$0.23
Net Loss Per Share Applicable to Common Stockholders - Diluted (in Dollars per share)	-$3.38+43.4%	-$5.97-7.2%	-$5.57	—
Basic (in Shares)	11.1M+64.5%	6.7M+11.2%	6.1M-95.9%	146.1M
Diluted (in Shares)	11.1M+64.5%	6.7M+11.2%	6.1M	—

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.